Search - tctmd.com

Displaying 361 - 380 of 397

Sort: Relevancy | Date

News Daily News

Drug-Eluting Balloon Continues Strong Showing in SFA Lesions

Jason Kahn

March 22, 2012

News Daily News

Se Publica el TARGET-CABG: El Período de Espera al CABG depende de la Prueba de la Función Plaquetaria

Yael L. Maxwell

March 15, 2012

News Daily News

El Apixaban Previene el ACV en Pacientes con Fibrilación Auricular con independencia de sus Antecedentes de ACV/AIT

L.A. McKeown

March 12, 2012

News Daily News

New-Onset A-fib After Percutaneous Valve Repair More Common Than Thought

December 13, 2011

News Conference News

PRISM Individualized Informed Consent Improves PCI Choice, Experience

November 14, 2011

News Industry News

Bayer HealthCare's Cotavance Drug Eluting Balloon With Paccocath Technology Reduced Five-Year Target Lesion Revascularization Rates

November 09, 2011

News Industry News

Bayer cooperates with Ludwig Boltzmann Institute for Translational Heart Failure Research

November 08, 2011

News Industry News

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

November 04, 2011

News Industry News

Bayer HealthCare's MEDRAD Interventional Business Announces Five-Year Data of Cotavance® Drug Eluting Balloon with Paccocath® Technology to be Presented at 2011 TCT

November 03, 2011

News Daily News

Hope Renewed for Novel Anticoagulant Use in ACS

Caitlin E. Cox

October 05, 2011

News Industry News

Bayer AG: Phase III Study of Bayer’s Rivaroxaban in Patients with Acute Coronary Syndrome Meets Primary Efficacy Endpoint

September 29, 2011

News Daily News

Rivaroxaban Continues Emergence of New Class of Anticoagulants for A-Fib

Caitlin E. Cox

September 14, 2011

News Daily News

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

L.A. McKeown

September 13, 2011

News Industry News

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

September 08, 2011

News Conference News

Novel Anticoagulants Showing Benefits in A-fib Subgroups

August 29, 2011

News Daily News

ROCKET AF Published: Rivaroxaban Matches Warfarin in Treating A-Fib Patients

Caitlin E. Cox

August 10, 2011

News Daily News

ARISTOTLE Makes Its Case: Apixaban Noninferior to Warfarin in A-fib

June 24, 2011

News Conference News

EuroPCR 2011: Novel Technologies with Transformative Potential Stand Out

May 23, 2011

News Conference News

Paclitaxel Balloon Maintains Advantage at 5 Years

Caitlin E. Cox

May 20, 2011

News Conference News

Osmolality, Viscosity Make No DIRECT Difference in Contrast Nephropathy

Jason Kahn

May 18, 2011

Advertisement

Drug-Eluting Balloon Continues Strong Showing in SFA Lesions

Se Publica el TARGET-CABG: El Período de Espera al CABG depende de la Prueba de la Función Plaquetaria

El Apixaban Previene el ACV en Pacientes con Fibrilación Auricular con independencia de sus Antecedentes de ACV/AIT

New-Onset A-fib After Percutaneous Valve Repair More Common Than Thought

PRISM Individualized Informed Consent Improves PCI Choice, Experience

Bayer HealthCare's Cotavance Drug Eluting Balloon With Paccocath Technology Reduced Five-Year Target Lesion Revascularization Rates

Bayer cooperates with Ludwig Boltzmann Institute for Translational Heart Failure Research

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

Bayer HealthCare's MEDRAD Interventional Business Announces Five-Year Data of Cotavance® Drug Eluting Balloon with Paccocath® Technology to be Presented at 2011 TCT

Hope Renewed for Novel Anticoagulant Use in ACS

Bayer AG: Phase III Study of Bayer’s Rivaroxaban in Patients with Acute Coronary Syndrome Meets Primary Efficacy Endpoint

Rivaroxaban Continues Emergence of New Class of Anticoagulants for A-Fib

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

Novel Anticoagulants Showing Benefits in A-fib Subgroups

ROCKET AF Published: Rivaroxaban Matches Warfarin in Treating A-Fib Patients

ARISTOTLE Makes Its Case: Apixaban Noninferior to Warfarin in A-fib

EuroPCR 2011: Novel Technologies with Transformative Potential Stand Out

Paclitaxel Balloon Maintains Advantage at 5 Years

Osmolality, Viscosity Make No DIRECT Difference in Contrast Nephropathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content